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Introduction
Multiple sclerosis (MS) is an autoimmune disorder in which the central nervous system (CNS) is targeted by the dysregulated activity of the immune system, resulting in progressive neurological dysfunction. A variety of symptoms characterize MS, among them are visual and motor problems, changes in sensation in the arms, legs or face and weakness. At the onset of the disease, 85-90% of the patients present a clinical course characterized by discrete attacks followed by periods of partial or total recovery (relapsingremitting MS, RRMS); 10% of the patients present a slowly accumulating disability over time (primary progressive MS, PPMS). A total of 40% of the patients initially diagnosed with RRMS eventually become progressive (secondary progressive MS, SPMS). The term MS refers to the scars (scleroses or plaques) that characterize the white matter of the brain and spinal cord of MS patients. The autoimmune attack that drives MS is thought to cause these scars, characterized by a perivascular infiltration by inflammatory cells (B and T lymphocytes among them)
. In addition, demyelination, astrogliosis and axonal injury are also detected [1, 2] . Different mechanisms contribute to axonal damage, including the direct effects of pro-inflammatory cytokines, complement fixation, apoptosis, cell-mediated cytotoxicity and neurodegeneration [1, 2] . Pathological findings suggest that the relative contribution of each one of these processes in disease progression differs in each patient [3] .
The autoimmune response in MS targets components of the myelin sheaths surrounding neuronal axons, interfering with the neurons' ability to conduct electrical signals and probably leading to their death. Several CNS proteins are targeted by the immune system in MS, among them are myelin oligodendrocyte glycoprotein [4] , oligodendrocyte-specific protein [5] , myelin basic protein [6] , myelin-associated glycoprotein [7] , 2Ј,3Ј-cyclic nucleotide 3Ј phosphodiesterase [8] and ␣␤-crystallin [9] . It is believed that the clinical symptoms that characterize MS result from the blockade in axonal transmission that follows axonal demyelination or axonal loss [1, 2] [21] . IL-7 is produced by stromal cells in lymphoid tissues, its availability is controlled through its uptake by the membrane-bound IL-7R on T cells [23] . Thus, considering the positive effects that IL-7 has on lymphocyte survival and proliferation [23] , the decrease in membrane IL-7R might result in increased levels of IL-7 available to fuel the inflammatory T-cell response in MS.
The ␣ chain IL-2 receptor (IL-2R␣) gene has also been recently linked to MS [22] . IL-2R␣ allelic variation has been previously associated to other autoimmune diseases such as type I diabetes, but at a different genomic position [24] . IL-2 is required for the development of regulatory T cells (Treg) [25, 26] [40] . To study the mechanism of action of OPN in MS, OPNdeficient mice were generated, which showed a reduced severity in EAE [34] . 
OPN-triggered signalling is thought to contribute to MS pathogenesis by increasing the pro-inflammatory phenotype and survival of pathogenic myelin-specific T cells [41]. In addition, OPN interacts with the ␣4-integrin and is also involved in cell migration into the inflamed CNS [42]. Neutralization of OPN with neutralizing antibodies results in the amelioration of EAE [43]. Thus, OPN is therefore an example of how results obtained in transcriptomics studies might lead to the identification of mechanisms of disease pathogenesis and new therapeutic targets for MS.
Characterization of the immune response
Identification of new pathogenic processes
Recently a large proteomic study of MS lesions by Steinman and coworkers have identified tissue factor and protein C inhibitor expression within chronic active plaque samples, suggesting that the dysregulation of the clotting cascade contributes to MS pathogenesis [49] .
The authors went on to investigate the potential therapeutic use of their findings on EAE, concluding that the coagulation cascade is an attractive therapeutic target in MS.
Role of environmental triggers in MS
Epidemiological studies suggest that environmental factors contribute to MS susceptibility. As a result, several groups are actively searching for microbial triggers for MS [10] [11] [12] [13] [14] [15] . One of these putative triggers is the Epstein-Barr Virus (EBV) [50] . [53] .
The link between EBV infection and MS has been recently strengthened by the work of Cepok and coworkers, who used protein expression arrays to characterize the antibody reactivity in the cerebrospinal fluid (CSF) of MS patients, most of those antibodies recognized EBV epitopes [51]. These results, together with the detection of EBV reactivation in active MS lesions [52], suggest that EBV might elicit an abnormal immune response in susceptible individuals that contributes to MS
Characterization of the autoimmune response: antibodies
The autoimmune nature of MS suggests that the study of the immune response should be useful for the early diagnosis, prognosis and monitoring of MS patients. T cells are thought to make a major contribution to MS immuno-pathology [16] , but the standardized characterization of the T-cell response has proven difficult in MS. Antibodies might also have a pathological role [54] . [56, 57] .
Moreover, the activation of antibody-producing B cells is controlled by T cells, thus antibody response is thought to reflect the activity of the T-cell compartment [55]. Since it is easier to assay antibody reactivity than to follow antigen-specific T-cell responses, new technologies have been developed for monitoring the humoural response in MS patients and autoimmunity
Antigen arrays have been shown to detect changes in the repertoire of antibodies reflecting the antigen spreading that accompanies EAE progression [58] . The information obtained about the antigen spreading was used to design tailored immunomodulatory vaccines to control EAE [58] . Of note, these vaccines showed promising results in a phase 1/2 human clinical trial [59] . [60] , autoimmune diabetes [57] and systemic lupus erythematosus [61] . Indeed, our own data suggest that antigen arrays might be used to identify antibody patterns linked to the different forms of MS and identify pathogenic mechanisms and therapeutic targets (F. J. Quintana et al., submitted) . Thus, antigen arrays are promising platforms for the identification of patients at risk of developing MS, before the overt onset of the symptoms [57] .
Future experiments should study the antibody response in the serum of MS patients, searching for patterns of antibody reactivity that predict the progression of MS or the response to therapy, as it was shown for other autoimmune disorders, such as rheumatoid arthritis
Metabolomics
The metabolome is defined as 'the complete set of small-molecule metabolites (such as metabolic intermediates, hormones and other signalling molecules, and secondary metabolites) to be found within a biological sample, such as a single organism' [62] . Although initial studies aimed at studying the metabolome in simple organisms like the yeast [63] , the study of a limited subset of the human metabolome in health and disease is well underway [64, 65] . Several groups have undertaken the study of metabolomic aspects of MS. [66] . Nitric oxide metabolites can be detected in CSF, serum and urine of MS patients, and their levels seem to reflect the activity of inflammatory processes that contribute to the pathology of the disease [66] [67] [68] . [69] [70] [71] [72] [73] . Although preliminary, these results suggest that metabolomics might provide sensitive biomarkers to follow up changes in the neurodegenerative and inflammatory processes that contribute to MS pathogenesis [74] . [75] . Strikingly, they found that the chromosomal domains containing the genes differentially expressed in autoimmune disorders could be mapped to disease susceptibility loci associated to those diseases by genetic linkage studies [75] [77] . Invertebrates lack adaptive immunity, but the zebrafish (Danio rerio) harbours an adaptive immune system that resembles the mammalian immune system [78] and offers several experimental advantages for the study of pathways controlling vertebrate processes of interest. As part of our work on the zebrafish to identify pathways controlling immunity, we have characterized the zebrafish homologues of the transcription factors autoimmune regulator [79] and Foxp3 [80, 81] [83] . However, the data generated by these highthroughput approaches should be integrated to understand how the genomics, transcriptomics and proteomics of an individual influence each other. This would require the development of computational tools for the integration of networks and pathways into accurate quantitative models [84, 85] ; with user interfaces aimed at facilitating its exploration and modification [86] . 
During the course of MS, macrophages and astrocytes produce nitric oxide, a metabolite that is thought to contribute to several aspects of MS pathology such as the disruption of the blood-brain barrier, oligodendrocyte injury and demyelination, axonal degeneration
N-acetylaspartate (NAA) is only present in living mature neurons, thus decreases in NAA levels indicate neuronal loss. Magnetic resonance (MR)-based approaches have been successfully used to measure the levels of NAA and other metabolites
Integration of data from different 'omics' approaches
The combination of the data generated in transcriptomics and genomics studies can be an invaluable source of information and new hypotheses. Aune et al. compared the genes differentially expressed by lymphocytes in rheumatoid arthritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus and MS, concluding that they are clustered within chromosomal domains in the genome
MS results from
